Chardan Capital Reiterates Buy on EyePoint Pharmaceuticals, Maintains $22 Price Target
Portfolio Pulse from richadhand@benzinga.com
Chardan Capital analyst Daniil Gataulin has reiterated a 'Buy' rating on EyePoint Pharmaceuticals (NASDAQ:EYPT) and maintained a price target of $22.
August 04, 2023 | 12:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
EyePoint Pharmaceuticals has received a reiterated 'Buy' rating from Chardan Capital, with a maintained price target of $22.
The reiterated 'Buy' rating and maintained price target by Chardan Capital indicates a positive outlook for EyePoint Pharmaceuticals. This could potentially lead to increased investor confidence and a short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100